Navigation Links
Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
Date:9/14/2010

gest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's CRF program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's CRF program include, but are not limited to, risk that GSK may terminate its development of GSK561679 and/or its collaboration with the Company;  risk that the ongoing GSK561679 clinical trials will fail to demonstrate that GSK561679 is safe and effective; risk that the Company's CRF program backup product candidates will not prove suitable for clinical development; risk that the Company will be unable to raise additional funding required to complete development of its CRF program product candidates; risk associated with the Company's dependence on corporate partners for future clinical development, commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's CRF program products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2009 and reports on Form 10-Q for the quarter ende
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
4. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
5. Neurocrine Biosciences, Inc. Prices Common Stock Offering
6. Neurocrine Announces Proposed Public Offering of Common Stock
7. Neurocrine Advances VMAT2 Inhibitor Program
8. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Neurocrine Biosciences Reports Third Quarter 2009 Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
11. Neurocrine Biosciences Presents Elagolix Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 According to ... Research "Global Market Study on Physiotherapy Equipment - ... Growth by 2022", the global physiotherapy equipment market is estimated ... of 2015 and is expected to grow at ... to account for US$23.7 Bn by 2022. ...
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... an Anti-TNF Alpha Antibody Fragment in Patients Undergoing ... a leading developer of antibody fragment therapeutics, today ... in patients undergoing cataract surgery. This study is ... pharmacokinetics (PK) of topically applied ESBA105 in patients, ...
... adults who are heavy users of marijuana are ... development, according to a new study. Pediatric researchers ... interconnect brain regions involved in memory, attention, decision-making, ... of particular concern because adolescence is a crucial ...
Cached Medicine Technology:ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology 2ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology 3ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology 4Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 2Heavy Marijuana Use May Damage Developing Brain in Teens, Young Adults 3
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact ... AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation ... an organization whose mission is to develop technology for the sake of humanity ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing ... the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le ... of the Company’s presentation may be accessed via the investor relations section of the ...
(Date:8/3/2015)... Los Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... trend has emerged among U.S. emergency rooms in recent years, according to the American ... 2012, the number of dental emergency visits went from 1.1 million in a single ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... - MDS Pharma,Services, a leading provider of innovative ... in Sao Paulo, Brazil, to provide,expanded capabilities in ... two dozen other MDS Pharma Services late stage ... Asia Pacific, Europe, Latin,America and North America. The ...
... fact of life that everyone,has problems. But, unfortunately, some ... with mental illness, addiction, or,HIV/AIDS often face challenges that ... Dealing with illness is often a lonely,heartbreaking experience that ... battle such things have an online hub in WebTribes,( ...
... HOUSTON, Jan. 28 While many of today,s seniors ... relaxed, enjoyable way of life,they want to stay connected ... and have access to trustworthy information and resources. In,addition, ... - anything from,obtaining referrals for home repairs to coordinating ...
... Mich., Jan. 28 Lawrence A. Roehrig,Secretary-Treasurer of ... County and Municipal Employees (AFSCME), AFL-CIO, issued the,following ... Hurley Medical Center, Flint, from 3:30 PM to ... 1603 has been at the bargaining table with ...
... protease ... ABBOTT PARK, Ill., Jan. 28 Abbott (NYSE: ... Medicinal Products for Human Use,(CHMP), the scientific committee of ... recommending approval of a new,lower-strength tablet formulation of the ...
... Europe for the Treatment of ... with Metastatic Colorectal Cancer, BASEL, Switzerland, Jan. 28 ... approval for the significantly,wider use of its anti-angiogenic agent Avastin(bevacizumab) ... label will now allow Avastin to be used in combination,with ...
Cached Medicine News:Health News:MDS Pharma Services Expands Presence in Latin America with Sao Paulo Office 2Health News:MDS Pharma Services Expands Presence in Latin America with Sao Paulo Office 3Health News:WebTribes Offers Online Home for Those with Illnesses 2Health News:Senior Citizens Bureau Empowers Today's Seniors: National Non-profit Serves as Community Resource for Seniors, Their Children, Caregivers and Even Advocates 2Health News:Senior Citizens Bureau Empowers Today's Seniors: National Non-profit Serves as Community Resource for Seniors, Their Children, Caregivers and Even Advocates 3Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 2Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 3Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 4Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 5Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 6Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 7Health News:Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA 8Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 2Health News:Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: